

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Suoxinda Holdings Limited**

**索信达控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 3680)**

### **POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 24 OCTOBER 2022**

Reference is made to the circular (the “**Circular**”) and the notice (the “**Notice**”) of Suoxinda Holdings Limited (the “**Company**”) both dated 1 October 2022 regarding the extraordinary general meeting (“**EGM**”) held on 24 October 2022. Unless otherwise stated, terms used herein shall have the same meanings as defined in the Circular, unless the context requires otherwise.

The Board is pleased to announce that all the resolutions (the “**Resolution(s)**”) as set out in the Notice were duly passed by way of poll at the EGM.

Directors of the Company, namely Mr. Song Hongtao, Mr. Chen Zhenping, Dr. Wu Fu-Shea, Mr. Wu Xiaohua, Mr. Tu Xinchun, Dr. Chen Wei and Mr. Yang Haifeng, had attended the EGM.

The poll results are as follows:

Ordinary Resolutions		Number of Votes (%) <i>(Note (a))</i>	
		For	Against
1.	<p>(a) the subscription agreement (the “<b>Subscription Agreement</b>”) dated 1 September 2022 entered into between the Company and Mr. Shi Banchao (“<b>Mr. Shi</b>”) and the transactions contemplated thereunder, including but not limited to, the allotment and issue of 32,000,000 new shares of the Company (the “<b>Subscription Shares</b>”) to Mr. Shi, be and is hereby approved, confirmed and ratified;</p> <p>(b) subject to and conditional upon the Listing Committee of Stock Exchange having granted the listing of, and permission to deal in the 32,000,000 Subscription Shares, the directors of the Company (the “<b>Directors</b>”) be and are hereby granted the specific mandate (the “<b>Specific Mandate</b>”) which shall entitle the Directors to exercise all the powers of the Company to issue and allot 32,000,000 Subscription Shares to Mr. Shi, on and subject to the terms and conditions of the Subscription Agreement entered into between the Company and Mr. Shi, provided that the Specific Mandate shall be in addition to, and shall not prejudice nor revoke any general or specific mandate(s) which has/have been granted or may from time to time be granted to the Directors prior to the passing of this resolution; and</p> <p>(c) any one Director be and is hereby authorised to, on behalf of the Company, do all such acts and things, to sign and execute such documents or agreements or deeds and take all such actions as he/she/they may in his/her/their absolute discretion consider necessary, appropriate, desirable or expedient for the purposes of giving effect to or in connection with the Subscription Agreement entered into between the Company and Mr. Shi and the transactions contemplated thereunder and agree to such variation, amendment or waiver as are, in the opinion of such Director, in the interest of the Company and the Shareholders as a whole.</p>	166,708,092 (100.00%)	0 (0.00%)

Ordinary Resolutions		Number of Votes (%) <i>(Note (a))</i>	
		For	Against
2.	<p>(a) the Subscription Agreement dated 1 September 2022 entered into between the Company and Dr. Wu Fu-Shea (“<b>Dr. Wu</b>”) and the transactions contemplated thereunder, including but not limited to, the allotment and issue of 5,450,000 Subscription Shares to Dr. Wu, be and is hereby approved, confirmed and ratified;</p> <p>(b) subject to and conditional upon the Listing Committee of Stock Exchange having granted the listing of, and permission to deal in the 5,450,000 Subscription Shares, the Directors be and are hereby granted the Specific Mandate which shall entitle the Directors to exercise all the powers of the Company to issue and allot 5,450,000 Subscription Shares to Dr. Wu, on and subject to the terms and conditions of the Subscription Agreement entered into between the Company and Dr. Wu, provided that the Specific Mandate shall be in addition to, and shall not prejudice nor revoke any general or specific mandate(s) which has/have been granted or may from time to time be granted to the Directors prior to the passing of this resolution; and</p> <p>(c) any one Director be and is hereby authorised to, on behalf of the Company, do all such acts and things, to sign and execute such documents or agreements or deeds and take all such actions as he/she/they may in his/her/their absolute discretion consider necessary, appropriate, desirable or expedient for the purposes of giving effect to or in connection with the Subscription Agreement entered into between the Company and Dr. Wu and the transactions contemplated thereunder and agree to such variation, amendment or waiver as are, in the opinion of such Director, in the interest of the Company and the Shareholders as a whole.</p>	160,708,092 (100.00%)	0 (0.00%)

Ordinary Resolutions		Number of Votes (%) <i>(Note (a))</i>	
		For	Against
3.	<p>(a) the Subscription Agreement dated 1 September 2022 entered into between the Company and Ms. Wang Jing (“<b>Ms. Wang</b>”) and the transactions contemplated thereunder, including but not limited to, the allotment and issue of 300,000 Subscription Shares to Ms. Wang, be and is hereby approved, confirmed and ratified;</p> <p>(b) subject to and conditional upon the Listing Committee of Stock Exchange having granted the listing of, and permission to deal in the 300,000 Subscription Shares, the Directors be and are hereby granted the Specific Mandate which shall entitle the Directors to exercise all the powers of the Company to issue and allot 300,000 Subscription Shares to Ms. Wang, on and subject to the terms and conditions of the Subscription Agreement entered into between the Company and Ms. Wang, provided that the Specific Mandate shall be in addition to, and shall not prejudice nor revoke any general or specific mandate(s) which has/have been granted or may from time to time be granted to the Directors prior to the passing of this resolution; and</p> <p>(c) any one Director be and is hereby authorised to, on behalf of the Company, do all such acts and things, to sign and execute such documents or agreements or deeds and take all such actions as he/she/they may in his/her/their absolute discretion consider necessary, appropriate, desirable or expedient for the purposes of giving effect to or in connection with the Subscription Agreement entered into between the Company and Ms. Wang and the transactions contemplated thereunder and agree to such variation, amendment or waiver as are, in the opinion of such Director, in the interest of the Company and the Shareholders as a whole.</p>	166,708,092 (100.00%)	0 (0.00%)

*Notes:*

- (a) the number and percentage of votes are based on the total number of Shares of the Company voted by the Shareholders of the Company at the EGM in person or by proxy.
- (b) As all the votes were cast in favour of each of the Resolutions numbered 1 to 3, all Resolutions were duly passed as ordinary resolutions.
- (c) The total number of Shares of the Company in issue as at the date of the EGM: 439,793,036 Shares.
- (d) As at the date of the EGM, Mr. Shi, Dr. Wu and Ms. Wang, holding 825,835 Shares, 6,000,000 Shares and 1,507,000 Shares (among which 59,835 Shares of Mr. Shi and 195,000 Shares of Ms. Wang are unvested Restricted Shares held by the trustee who shall not exercise the voting rights in respect of such unvested Restricted Shares pursuant to the rules of the Share Award Scheme), representing approximately 0.19%, 1.36% and 0.34% of the issued Shares as at the date of the EGM respectively, were required to abstain and had abstained voting in the Resolutions numbered 1, 2 and 3 at the EGM respectively. Accordingly, the total number of shares of the Company entitling the holder to attend and vote on the Resolutions numbered 1, 2 and 3 at the EGM were 438,967,201, 433,793,036 and 438,286,036 Shares respectively.
- (e) There were no Shares entitling the holder to attend and abstain from voting in favour of the Resolutions at the EGM as set out in Rule 13.40 of the Listing Rules.
- (f) Save as disclosed above, no other Shareholder of the Company was required under the Listing Rules to abstain from voting on the Resolutions at the EGM.
- (g) None of the Shareholders of the Company have stated their intention in the Circular to vote against or to abstain from voting on any of the resolutions at the EGM.
- (h) The Company's Hong Kong Branch Share Registrar, Tricor Investor Services Limited, acted as the scrutineer for the vote-taking at the EGM.

**By order of the Board**  
**Suoxinda Holdings Limited**  
**Song Hongtao**  
*Chairman of the Board*

Hong Kong, 24 October 2022

*As at the date of this notice, the Board comprises four executive Directors, namely, Mr. Song Hongtao, Mr. Chen Zhenping, Dr. Wu Fu-Shea and Mr. Wu Xiaohua, and three independent non-executive Directors, namely, Mr. Tu Xinchun, Dr. Chen Wei and Mr. Yang Haifeng.*